Clinical Trials

Disease Chronic Plaque Psoriasis
Title A comparison between the microbial flora of normal human skin and skin from patients with psoriasis and other inflammatory conditions using broad-range PCR
Inclusion* Moderate to severe psoriasis patients who are not currently under treatment (baseline visit) and are eligible to receive either methotrexate or adalimumab (week 12 and 36 visit)
Study Contact Elizabeth.Camacho@nyumc.org
Principal Investigator Dr. Martin Blaser
Objective To evaluate the cutaneous microbial flora. No study agents will be administered in this study. All patients will receive standard of care treatments prescribed by the patient's physician.
Status RECRUITING
Age Requirement 18-75 years of age
Gender males and females

 

Disease Pityriasis Rubra Pilaris
Title A comparison between the microbial flora of normal human skin and skin from patients with psoriasis and other inflammatory conditions using broad-range PCR
Inclusion* Pityriasis rubra pilaris patients who are not currently under treatment
Study Contact Elizabeth.Camacho@nyumc.org
Principal Investigator Dr. Martin Blaser
Objective To evaluate the cutaneous microbial flora. No study agents will be administered in this study. All patients will receive standard of care treatments prescribed by the patient's physician.
Status RECRUITING
Age Requirement 18-75 years of age
Gender males and females

 

 Disease Chronic Plaque Psoriasis
Title Phase 2a, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of a new oral medication in subjects with moderate to severe psoriasis
Inclusion* Stable moderate to severe chronic plaque psoriasis for at least 6 months
Study Contact Elizabeth.Camacho@nyumc.org
Principal Investigator Dr. Jerome Shupack
Objective To evaluate the safety and efficacy of a new treatment
Status RECRUITING
Age Requirement 18-80 years of age
Gender males and females*

 

Disease Chronic Plaque Psoriasis
Title Multi-center, open registry of patients with psoriasis who are candidates for systemic therapies including biologics
Inclusion* Patients with all forms of psoriasis receiving systemic therapy
Study Contact Elizabeth.Camacho@nyumc.org
Principal Investigator Dr. Jerome Shupack
Objective Registry study to evaluate the safety and efficacy of systemic treatments for psoriasis. No study agents will be administered in this registry. All patients will receive standard of care treatments prescribed by the patient's physician.
Status RECRUITING
Age Requirement ≥ 18 years of age
Gender males and females

 Disease Chronic Plaque Psoriasis
 Title A phase 3, multi-site, randomized, double-blind, placebo-controlled, paralle-group study of the efficacy and safety of 2 doses of a new oral medication in subjects with moderate to severe chronic plaque psoriasis
 Inclusion*  Stable moderate to severe chronic plaque psoriasis for at least 6 months
 Study Contact  Elizabeth.Camacho@nyumc.org
 Principal investigator  Dr. Jerome Shupack
 Objective  To evaluate the safety and efficacy of a new treatment
 Status  Recruitment will start soon
 Age Requirement  ≥ 18 years of age
 Gender  males and females*

 Disease Chronic Plaque Psoriasis
 Title A phase 3, multi-site, open-label study of the long term safety and tolerability of 2 oral doses of a new medication in subjects with moderate to severe chronic plaque psoriasis
 Inclusion*  Participation in the above mentioned study
 Study Contact  Elizabeth.Camacho@nyumc.org
 Principal Investigator  Dr. Jerome Shupack
 Objective  To evaluate the long term safety and efficacy of a new treatment
 Status  Recruitment will start soon
 Age Requirement  ≥ 18 years of age
 Gender  males and females*

Disease Discoid and Subacute Cutaneous Lupus Erythematosus
Title Phase 2, pilot, multicenter, ascending dose study to evaluate the preliminary safety and efficacy of a new oral medication to treat discoid lupus erythematosus and subacute cutaneous lupus erythematosus
Inclusion* Men and women, who are 18 years of age or older with a biopsy-proven diagnosis of cutaneous discoid lupus. No evidence of systemic lupus (involvement of internal organs and/or inflammation of blood vessels or joints).
Study Contact Elizabeth.Camacho@nyumc.org
Principal Investigator Dr. Andrew G. Franks
Objective To evaluate the clinical response of discoid lupus patients to an investigational oral medication
Status RECRUITING
Age Requirement ≥ 18 years of age
Gender males and females*

 *: Required for all studies: females of childbearing age must have a negative pregnancy test at screening and agree to use at least two forms of contraception during their participation in the study.

For complete information regarding inclusion and exclusion criteria, please call 212-263-5244 or email Elizabeth.Camacho@nyumc.org